Abstract
In contrast to conventional stem cell transplantation which utilizes high-dose chemotherapy and/or total body irradiation as a conditioning regimen, non-myeloablative stem cell transplantation (NST) uses mainly immunosuppressants. NST is now being used to treat solid tumors, as it greatly alleviates regimen-related toxicity. NST, which utilizes the graft-versus-tumor effect as an anti-tumor weapon, is considered to be one type of immunotherapy. Ongoing clinical studies in the U.S. and Europe as well as in Japan are producing promising results for renal cell carcinoma and other tumors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 461-466 |
| Number of pages | 6 |
| Journal | Biotherapy |
| Volume | 15 |
| Issue number | 4 |
| State | Published - 2001 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Cancer Research
- Immunology and Allergy
Fingerprint
Dive into the research topics of 'Application of non-myeloablative allogeneic stem cell transplantation to solid tumors'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver